TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1609547
Drug: CVD 908
Normalized name: Vibrio cholerae CVD 103-HGR strain live antigen Oral Suspension [Vaxchora]
Approvals — FDA: no, EMA: no, PMDA: no
Description: CVD 908 Salmonella typhi vaccine strain (5 x 10(4) to 5 x 10(7) organisms with sodium bicarbonate)
Study: 26911400
Drug: Triamcinolone (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triamcinolone (10 mg/ml)
Study: 25002723
Drug: Cisplatin 30
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin 30 mg/m(2) once per week with 60 Gy radiation and cetuximab once per week
Study: 25002723
Drug: Docetaxel 15
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 15 mg/m(2) once per week with 60 Gy radiation and cetuximab once per week
Study: 20955444
Drug: Esomeprazole 20
Normalized name: esomeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 20 mg b.d.
Study: 20955444
Drug: Esomeprazole 20
Normalized name: esomeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 20 mg od before breakfast
Study: 20955444
Drug: Esomeprazole 40
Normalized name: esomeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 40 mg od before breakfast
Study: 20955444
Drug: Esomeprazole 40
Normalized name: esomeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 40 mg od before dinner or at bedtime
Study: 18572351
Drug: 100 mL
Normalized name: PVC IV Bag 100 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mL of 10% dextran-40
Study: 16138948
Drug: Device therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Device therapy
Study: 12436372
Drug: Glucocorticoids and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucocorticoids and non-steroidal antirheumatic drugs (NSAD)
Study: 12436372
Drug: TNF-alpha-inhibiting drugs
Normalized name: alpha 1-antitrypsin
DrugBank: Alpha-1-proteinase inhibitor (DB00058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TNF-alpha-inhibiting drugs (etanercept, infliximab)
Study: 11147027
Drug: 750 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750 micrograms Fluticasone propionate (FP) twice daily for 3 months
Study: 9176748
Drug: Intrapleurally instilled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrapleurally instilled mitoxantrone (30 mg)
Study: 10621528
Drug: Oral acyclovir
Normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral acyclovir as prophylaxis against recurrent stromal keratitis
Study: 9766780
Drug: Cognitive behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioral treatment of residual symptoms
Study: 21169002
Drug: Montelukast (CysLT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast (CysLT receptor 1 antagonist)
Study: 19906343
Drug: ORAL
Normalized name: Doral
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ORAL
Study: 11948850
Drug: Nevirapina (test
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nevirapina (test formulation)
Study: 11948850
Drug: Viramune (reference
Approvals — FDA: no, EMA: no, PMDA: no
Description: Viramune (reference formulation)
Study: 10407237
Drug: Continual low
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continual low dose corticosteroid treatment
Study: 511419
Drug: Intramuscular injection
Normalized name: rabies, intramuscular injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection of 0.2 mg/kg body weight pirenzepine
Study: 511419
Drug: Solvent injection
Normalized name: solvent yellow 18
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solvent injection (control)
Study: 24156306
Drug: Protocol A
Normalized name: Olay Professional Acne Protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocol A (12 mmol/l citrate, HCO3- 32 mmol/l replacement fluid)
Study: 24156306
Drug: Protocol B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocol B (18 mmol/l citrate with phosphate-containing dialysate/replacement fluid, HCO3- 30 mmol/l, Phosphate 1.2)
Study: 21335007
Drug: PegIFN therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: PegIFN therapy
Study: 19542983
Drug: Pregabalin 300-450
Normalized name: pregabalin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin 300-450 mg/day
Study: 19352198
Drug: Benzodiazepines (alprazolam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzodiazepines (alprazolam 1.5 mg/day; lorazepam 6 mg/day)
Study: 16723311
Drug: Formulation 1
Normalized name: Recombivax HB, Hepatitis B vaccine (recombinant) adult formulation 10 MCG per 1 ML Prefilled Syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulation 1 containing 250 mg vitamin C
Study: 16723311
Drug: Formulation 2
Normalized name: Hep B, unspecified formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulation 2 containing 250 mg vitamin C
Study: 16723311
Drug: Formulation 3
Normalized name: Hep B, unspecified formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulation 3 containing 250 mg vitamin C
Study: 9315597
Drug: Low-dose pravastatin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose pravastatin combined with low-dose cholestyramine
Study: 9315597
Drug: High-dose pravastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose pravastatin monotherapy
Study: 15015647
Drug: Heparin-coated circuits
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-coated circuits (HCC)
Study: 29579195
Drug: MST3 (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: MST3 (3 rounds of mass screening and treatment)
Study: 29579195
Drug: MST2 (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: MST2 (2 rounds of mass screening and treatment)
Study: 29579195
Drug: MST0 (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: MST0 (no mass screening and treatment)
Study: 27076772
Drug: Active care
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active care (6 mo colonoscopy and drug intensification for endoscopic recurrence)
Study: 27076772
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care (drug therapy without early endoscopy)
Study: 25420889
Drug: Lansoprazole (LS)
Normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lansoprazole (LS) 30mg once daily for 4 weeks
Study: 25420889
Drug: Lansoprazole (LS)
Normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lansoprazole (LS) 30mg once daily for 1 week followed by Ecabet Sodium (ES) 1500mg twice daily for 3 weeks
Study: 20723034
Drug: Terutroban 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terutroban 1 mg day(-1)
Study: 20723034
Drug: Terutroban 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terutroban 2.5 mg day(-1)
Study: 20723034
Drug: Terutroban 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terutroban 5 mg day(-1)
Study: 20723034
Drug: Terutroban 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terutroban 10 mg day(-1)
Study: 20723034
Drug: Terutroban 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terutroban 30 mg day(-1)
Study: 16689755
Drug: Aspirin 75
Normalized name: aspirin 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 75 mg day(-1)
Study: 15892271
Drug: Shenqi Fuzheng
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shenqi Fuzheng Injection (SFI) plus chemotherapy (CT)
Study: 15892271
Drug: Chemotherapy (CT)
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (CT) only
Study: 12322846
Drug: Enaril 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enaril 5 mg tablets
Study: 10426610
Drug: Vaginal misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vaginal misoprostol (200 microg tablet for at least four hours)
Study: 10426610
Drug: Vaginal gemeprost
Normalized name: gemeprost
DrugBank: Gemeprost (DB08964)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal gemeprost (1.0 mg vaginal suppository for at least three hours)
Study: 7897139
Drug: Medical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical therapy or implantable cardioverter‐defibrillator therapy
Study: 30888737
Drug: CNTX‐4975 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: CNTX‐4975 0.5 mg
Study: 30888737
Drug: CNTX‐4975 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: CNTX‐4975 1.0 mg
Study: 28984010
Drug: rhFVIIa 25
Normalized name: rFVIIa
DrugBank: Coagulation factor VIIa Recombinant Human (DB00036)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhFVIIa 25 μg/kg
Study: 28984010
Drug: rhFVIIa 75
Normalized name: rFVIIa
DrugBank: Coagulation factor VIIa Recombinant Human (DB00036)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhFVIIa 75 μg/kg
Study: 28984010
Drug: rhFVIIa 225
Normalized name: rFVIIa
DrugBank: Coagulation factor VIIa Recombinant Human (DB00036)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhFVIIa 225 μg/kg
Study: 28984010
Drug: rhFVIIa (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhFVIIa (all doses)
Study: 21472665
Drug: Control (optimal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (optimal diet therapy, sulfonylurea and/or insulin)
Study: 11273919
Drug: Fentanyl continuous
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl continuous infusion (Group 2)
Study: 11273919
Drug: Fentanyl-midazolam infusion
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl-midazolam infusion (Group 3)
Study: 9298429
Drug: Primarily noradrenergic
Normalized name: Rauwolfia alkaloids, centrally acting antiadrenergic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primarily noradrenergic reuptake inhibitor (desipramine)
Study: 9298429
Drug: Selective serotonin
Normalized name: Selective serotonin (5HT1) agonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective serotonin reuptake inhibitors (SSRIs) (sertraline or paroxetine)
Study: 9298429
Drug: Combined serotonin
Normalized name: serotonin
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined serotonin and norepinephrine reuptake inhibitor (SNRI) (venlafaxine)
Study: 8420442
Drug: Fosinopril (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fosinopril (10 mg initial oral daily dose, then 20 mg once a day during open-label phase)
Study: 24819566
Drug: Darbepoetin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Darbepoetin (10 μg/kg, 1×/week subcutaneously)
Study: 24819566
Drug: Placebo (sham
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (sham dosing 3×/week)
Study: 12924802
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (acetaminophen, NSAIDs, and education)
Study: 10640258
Drug: Zolmitriptan (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolmitriptan (2.5 mg or 5 mg)
Study: 10640258
Drug: Zolmitriptan (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolmitriptan (5 mg)
Study: 2669067
Drug: APD (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: APD (300 mg/day orally)
Study: 71972
Drug: Flurbiprofen 150
Normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flurbiprofen 150 mg daily
Study: 71972
Drug: Flurbiprofen 150
Normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flurbiprofen 150 mg daily plus 3 g aspirin daily
Study: 29200944
Drug: Therapeutic cervical
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic cervical medial branch blocks (with or without steroids)
Study: 24121097
Drug: Internet-delivered cognitive
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-delivered cognitive behavioral treatment for insomnia with weekly email support
Study: 24121097
Drug: Internet-delivered cognitive
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-delivered cognitive behavioral treatment for insomnia without support
Study: 12950862
Drug: Intravenous remifentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous remifentanil
Study: 19812445
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg maraviroc
Study: 12730746
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg risedronate
Study: 12730746
Drug: Risedronate (1-5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risedronate (1-5 mg doses)
Study: 12730746
Drug: Risedronate (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risedronate (up to 5 mg)
Study: 2680843
Drug: RS 86
Normalized name: (RS)-bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: RS 86 (cholinergic agent)
Study: 25331469
Drug: Ropivacaine local
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine local infiltration (0.5% ropivacaine, 40 ml, n = 22)
Study: 25331469
Drug: Sodium chloride
Normalized name: Sodium Chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium chloride local infiltration (0.9% sodium chloride, 40 ml, n = 20)
Study: 25331469
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no analgesic, n = 19)
Study: 10343261
Drug: Intravenous triiodothyronine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous triiodothyronine (0.4 microgram/kg bolus plus 0.1 microgram/kg infusion over 6 hours, n = 81)
Study: 10343261
Drug: Intravenous triiodothyronine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous triiodothyronine
Study: 7594443
Drug: Nifedipine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (10 mg capsule)
Study: 7594443
Drug: Dihydralazine (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydralazine (intravenous infusion at a rate of 1-3 mg/h)
Study: 28586878
Drug: Dietary intake
Normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dietary intake of at least 500 mg/d of long-chain omega-3 polyunsaturated fatty acids (LCω3PUFAs)
Study: 25698759
Drug: Alcohol intoxication
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcohol intoxication (0.75 g/kg)
Study: 23345623
Drug: FIR therapy
Normalized name: Douglas fir pollen extract
DrugBank: Pseudotsuga menziesii pollen (DB10986)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FIR therapy (40 min, three times weekly for one year)
Study: 23345623
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no FIR therapy)
Study: 23345623
Drug: FIR therapy
Normalized name: Douglas fir pollen extract
DrugBank: Pseudotsuga menziesii pollen (DB10986)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FIR therapy
Study: 18663500
Drug: moxifloxacin 400
Normalized name: moxifloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: moxifloxacin 400 mg i.v. once daily
Study: 18663500
Drug: amoxicillin/clavulanic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: amoxicillin/clavulanic acid 2.2 g i.v. three times daily
Study: 18663500
Drug: moxifloxacin and
Approvals — FDA: no, EMA: no, PMDA: no
Description: moxifloxacin and amoxicillin/clavulanic acid
Study: 17227570
Drug: 15 microg/mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 microg/mL IDN-6556 (Organ storage/flush)
Study: 17227570
Drug: 5 microg/mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 microg/mL IDN-6556 (Organ storage/flush) + 0.5 mg/kg (Recipient)
Study: 17227570
Drug: 15 microg/mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 microg/mL IDN-6556 (Organ storage/flush) + 0.5 mg/kg (Recipient)
Study: 10863139
Drug: Gabapentin 400
Normalized name: gabapentin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin 400 mg single dose (Study A)
Study: 10863139
Drug: Gabapentin 600
Normalized name: gabapentin 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin 600 mg single dose (Study B)
Study: 7818840
Drug: Captopril (angiotensin-converting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (angiotensin-converting enzyme inhibitor)
Study: 29421001
Drug: Prehospital ticagrelor
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prehospital ticagrelor treatment
Study: 22305833
Drug: High-concentration oxygen
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-concentration oxygen therapy (6 L/min via medium concentration mask)
Study: 22305833
Drug: Titrated oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Titrated oxygen therapy (to achieve oxygen saturation 93%-96%)
Study: 18515518
Drug: One E2
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One E2 spray (1.53 mg E2, 90 microliter)
Study: 18515518
Drug: Two E2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two E2 sprays (3.06 mg E2, 180 microliter)
Study: 18515518
Drug: Three E2
Normalized name: THREE-LOBE SAGE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three E2 sprays (4.59 mg E2, 270 microliter)
Study: 9704785
Drug: 140 mg/dL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 140 mg/dL cutoff value in oral glucose challenge test
Study: 9704785
Drug: 142 mg/dL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 142 mg/dL cutoff value in oral glucose challenge test
Study: 9704785
Drug: 141 mg/dL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 141 mg/dL cutoff value in oral glucose challenge test
Study: 9704785
Drug: 136 mg/dL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 136 mg/dL cutoff value in oral glucose challenge test
Study: 8527690
Drug: HI-6 (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: HI-6 (500 mg) with atropine sulphate (2 mg)
Study: 1978503
Drug: D-phenylalanine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-phenylalanine (0.5 grams three times the day before treatment)
Study: 631733
Drug: Phenformin 50
Normalized name: phenformin 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenformin 50 mg every 12 hours for 3 days before and during the fasts
Study: 31506859
Drug: Cognitive Processing
Normalized name: Allogeneic processed thymus tissue
DrugBank: Allogeneic processed thymus tissue (DB16736)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Processing Therapy for Posttraumatic Stress Disorder
Study: 30144887
Drug: Top-D (Vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Top-D (Vitamin D3 gel made from proniosomal technology) applied daily on the skin, 1 g containing 5000 IU of vitamin D3
Study: 30144887
Drug: Aloe vera
Normalized name: ALOE VERA
DrugBank: Aloe vera leaf (DB13906)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aloe vera gel applied daily, 1 g
Study: 24585900
Drug: Modified St.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified St. Thomas' Hospital cardioplegic solution (group S)
Study: 24585900
Drug: Conventional glucose-insulin-potassium
Normalized name: glucose / potassium chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional glucose-insulin-potassium solution (group G)
Study: 7862844
Drug: 0.3 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 g/kg alcohol
Study: 7862844
Drug: 0.6 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6 g/kg alcohol
Study: 463982
Drug: Pelvic irradiation
Normalized name: Sus scrofa renal pelvis preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pelvic irradiation alone or followed by adjuvant daily chlorambucil therapy
Study: 30283182
Drug: Lidocaine 2
Normalized name: lidocaine 25 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 2 mg/kg/h with a maximum of 200 mg/h starting at induction of anesthesia until the end of surgery
Study: 30283182
Drug: Magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Magnesium sulfate 50 mg/kg iv bolus in 100ml saline over 10 min followed by infusion of 15 mg/kg/h until the end of surgery
Study: 22517399
Drug: Cilengitide 500
Normalized name: Cilengitide
DrugBank: Cilengitide (DB11890)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilengitide 500 mg with standard radiation and temozolomide
Study: 22517399
Drug: Cilengitide 2000
Normalized name: Cilengitide
DrugBank: Cilengitide (DB11890)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilengitide 2000 mg with standard radiation and temozolomide
Study: 22517399
Drug: Cilengitide (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilengitide (both doses) with standard radiation and temozolomide
Study: 19751434
Drug: Standard triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard triple therapy without Lactobacilli
Study: 12409967
Drug: Cortisol infusion
Normalized name: cortisol succinate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cortisol infusion (0.625, 1.25 and 2.5 microg/kg per min for 10 min each)
Study: 12409967
Drug: Glycyrrhetinic acid
Normalized name: Glycyrrhetinic Acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycyrrhetinic acid (GRA; 500 mg orally 2.5 h before the study)
Study: 9809729
Drug: Glipizide GITS
Normalized name: Glipizide
DrugBank: Glipizide (DB01067)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glipizide GITS (5 to 20 mg)
Study: 1000519
Drug: Cis-dichlorodiammineplatinum(II) high-dose
Normalized name: CIS-DIAMMINEDICHLOROPLATINUM II
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cis-dichlorodiammineplatinum(II) high-dose schedule (30 mg/m2 daily for 3 days every 4 weeks)
Study: 1000519
Drug: Cis-dichlorodiammineplatinum(II) low-dose
Normalized name: CIS-DIAMMINEDICHLOROPLATINUM II
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cis-dichlorodiammineplatinum(II) low-dose schedule (30 mg/m2 once every 2-3 weeks)
Study: 27401882
Drug: Prolonged release
Normalized name: EYE DROPS, PROLONGED RELEASE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged release oxycodone/naloxone (OXN PR)
Study: 24836758
Drug: Treatment groups
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment groups (specific treatments not detailed)
Study: 12856481
Drug: Increased digoxin
Normalized name: Digoxin
DrugBank: Digoxin (DB00390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Increased digoxin synthesis with upregulated tryptophan catabolism (increased serotonin, strychnine, nicotine) and downregulated tyrosine catabolism (decreased dopamine, noradrenaline, morphine) in chronic insomnia with right hemispheric dominance